Recent headlines swirling around the swine flu have centered the focus of both the public and investors on vaccines and the vaccine industry. The vaccine marketplace is expected to show big gains through 2012 as it emerges as one of the most lucrative sectors of the global pharmaceutical industry. This bodes well for innovative companies such as TapImmune Inc. (OTCBB: TPIV).

TapImmune is a biotechnology company specializing in the development of cell-based vaccines and immunotherapeutics in the areas of oncology and infectious disease. The company’s vaccine technology is based on modulating the activity of the antigen processing machinery to increase effective presentation of antigens to the immune system. Transporters associated with antigen processing (TAP) play a major role in the antigen processing pathway.

One of the most lucrative areas for vaccine makers is vaccines which may treat various forms of cancer. The company’s lead product candidate, the AdhTAP vaccine enhancer, is designed to restore and augment presentation and subsequent recognition and killing of cancer cells by the immune system. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer. TapImmune is currently planning the development of AdhTAP for the commencement of clinical manufacturing and toxicology studies.

TapImmune is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1,000 times. The company’s TAP technology could also enhance the creation of new vaccines in the fight against many pandemic infectious diseases.

Let us hear your thoughts: TapImmune, Inc. Message Board